$JNJ Johnson & Johnson Q3 Earnings

13 Oct 2026 10:21JNJ
  • Adj. EPS $2.59, est. $2.52
  • Revenue $24.60B, est. $24.21B
  • MedTech Sales $8.64B, est. $8.77B
  • Medicine Revenue $16.76B, est. $16.59B
  • Darzalex Revenue $4.24B, est. $4.31B
  • FY Adj. EPS Outlook $11.05–$11.15, prior $10.96–$11.11
  • FY Adj. Operating EPS Outlook $10.95–$11.05, prior $10.86–$11.01
  • FY Sales Outlook $101B–$101.4B, prior $100.8B–$101.4B
  • CFO: Leaning Toward Orthopedic Unit Spinoff Instead of Sale